Literature DB >> 7695248

Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.

J M Entenza1, M Blatter, M P Glauser, P Moreillon.   

Abstract

A new, investigational, parenteral form of sparfloxacin was compared with ceftriaxone in the treatment of experimental endocarditis caused by either of three penicillin-susceptible streptococci or one penicillin-resistant streptococcus. Both drugs have prolonged half-lives in serum, allowing single daily administration to humans. Sparfloxacin had relatively low MICs (0.25 to 0.5 mg/liter) for all four organisms and was also greater than or equal to eight times more effective than the other quinolones against 21 additional streptococcal isolates recovered from patients with bacteremia. Ceftriaxone MICs were 0.032 to 0.064 mg/liter for the penicillin-susceptible strains and 2 mg/liter for the resistant isolate. Both antibiotics resulted in moderate bacterial killing in vitro. Rats with catheter-induced aortic vegetations were inoculated with 10(7) CFU of the test organisms. Antibiotic treatment was started 48 h later and lasted either 3 or 5 days. The drugs were injected at doses which mimicked the kinetics in human serum produced by one intravenous injection of 400 mg of sparfloxacin (i.e., the daily dose expected to be given to human adults) and 2 g of ceftriaxone. Both antibiotics significantly decreased the bacterial densities in the vegetations. However, sparfloxacin was slower than ceftriaxone in its ability to eradicate valvular infection caused by penicillin-susceptible bacteria. While this difference was quite marked after 3 days of therapy, it tended to vanish when treatment was prolonged to 5 days. In contrast, sparfloxacin was very effective against the penicillin-resistant isolate, an organism against which ceftriaxone therapy failed in vivo. No sparfloxacin-resistant mutant was selected during therapy. Thus, in the present experimental setting, this new, investigational, parenteral form of sparfloxacin was effective against severe infections caused by both penicillin-susceptible and penicillin-resistant streptococci.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695248      PMCID: PMC188270          DOI: 10.1128/AAC.38.12.2683

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci.

Authors:  A L Bisno; W E Dismukes; D T Durack; E L Kaplan; A W Karchmer; D Kaye; S H Rahimtoola; M A Sande; J P Sanford; C Watanakunakorn
Journal:  JAMA       Date:  1989-03-10       Impact factor: 56.272

2.  Experimental bacterial endocarditis. I. Colonization of a sterile vegetation.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

3.  Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci.

Authors:  U Fluckiger; P Francioli; J Blaser; M P Glauser; P Moreillon
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

4.  Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children.

Authors:  C Odio; G H McCracken; J D Nelson
Journal:  J Pediatr       Date:  1984-09       Impact factor: 4.406

5.  Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis.

Authors:  V Joly; B Pangon; J M Vallois; L Abel; N Brion; A Bure; N P Chau; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  Natural history of aortic valve endocarditis in rats.

Authors:  E Héraïef; M P Glauser; L R Freedman
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

8.  Comparative efficacy of cefotiam, cefmenoxime, and ceftriaxone in experimental endocarditis and correlation with pharmacokinetics and in vitro efficacy.

Authors:  B Pangon; V Joly; J M Vallois; L Abel; A Buré; N Brion; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.

Authors:  C M Perronne; R Malinverni; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

10.  Pharmacokinetics of ceftriaxone in humans.

Authors:  I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

View more
  7 in total

1.  Comparative killing rates of fluoroquinolones and cell wall-active agents.

Authors:  J C Fung-Tomc; E Gradelski; L Valera; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.

Authors:  Paloma Anguita-Alonso; Mark S Rouse; Kerryl E Piper; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

Authors:  T M Murphy; J M Deitz; P J Petersen; S M Mikels; W J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

6.  Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis.

Authors:  D Vermot; J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Authors:  J M Entenza; O Marchetti; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.